Gouw Alida A, Alsema Astrid M, Tijms Betty M, Borta Andreas, Scheltens Philip, Stam Cornelis J, van der Flier Wiesje M
Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Clinical Neurophysiology and MEG Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Clinical Neurophysiology and MEG Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Neurobiol Aging. 2017 Sep;57:133-142. doi: 10.1016/j.neurobiolaging.2017.05.017. Epub 2017 Jun 1.
We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects. We included 205 nondemented amyloid positive subjects (63 subjective cognitive decline [SCD]; 142 mild cognitive impairment [MCI]) with a baseline resting-state EEG data and ≥1-year follow-up. Peak frequency and relative power of 4 frequency bands were calculated. Relationships between normalized EEG measures and time to clinical progression (conversion from SCD to MCI/dementia or from MCI to dementia) were analyzed using Cox proportional hazard models. One hundred eight (53%) subjects clinically progressed after 2.1 (IQR 1.3-3.0) years. In the total sample, none of the EEG spectral measures were significant predictors. Stratified for baseline diagnosis, we found that in SCD patients higher delta and theta power (HR [95% CI] = 1.7 [1.0-2.7] resp. 2.3 [1.2-4.4]), and lower alpha power and peak frequency (HR [95% CI] = 0.5 [0.3-1.0] resp. 0.6 [0.4-1.0]) were associated with clinical progression over time. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.
我们研究了源自脑电图（EEG）的脑振荡活动测量指标是否与非痴呆、淀粉样蛋白阳性受试者的临床进展相关。我们纳入了205名非痴呆淀粉样蛋白阳性受试者（63名主观认知下降[SCD]；142名轻度认知障碍[MCI]），他们有基线静息态EEG数据且随访时间≥1年。计算了4个频段的峰值频率和相对功率。使用Cox比例风险模型分析了标准化EEG测量指标与临床进展时间（从SCD转换为MCI/痴呆或从MCI转换为痴呆）之间的关系。108名（53%）受试者在2.1（四分位间距1.3 - 3.0）年后出现临床进展。在总样本中，没有EEG频谱测量指标是显著的预测因素。按基线诊断分层后，我们发现，在SCD患者中，较高的δ波和θ波功率（风险比[95%置信区间]分别为1.7[1.0 - 2.7]和2.3[1.2 - 4.4]），以及较低的α波功率和峰值频率（风险比[95%置信区间]分别为0.5[0.3 - 1.0]和0.6[0.4 - 1.0]）与随时间的临床进展相关。在认知正常的淀粉样蛋白阳性受试者中，脑振荡活动减慢与临床进展相关。
